Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis.
<h4>Background</h4>Intravitreal anti-vascular endothelial growth factor (VEGF) monoclonal antibodies are used in ocular neovascular diseases. A consensus has emerged that intravenous anti-VEGF can increase the risk of arterial thromboembolic events. However, the role of intravitreal anti...
Saved in:
Main Authors: | Jin-Wei Cheng, Shi-Wei Cheng, Guo-Cai Lu, Rui-Li Wei |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2012
|
Subjects: | |
Online Access: | https://doaj.org/article/749e069a68cd41bc9da7ac69440e23a1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents
by: Ruão M, et al.
Published: (2017) -
Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
by: Jihyun Yoon, et al.
Published: (2021) -
Incidence of outer retinal tubulation in eyes with choroidal neovascularization under intravitreal anti-vascular endothelial growth factor therapy in a Japanese population
by: Takagi S, et al.
Published: (2017) -
Author Correction: Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy
by: Jihyun Yoon, et al.
Published: (2021) -
Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
by: Tan CS, et al.
Published: (2017)